Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model.

[1]  Eric H Kim,et al.  Metabolite mapping reveals severe widespread perturbation of multiple metabolic processes in Huntington's disease human brain. , 2016, Biochimica et biophysica acta.

[2]  P. Órdenes,et al.  Cloning of two LIMCH1 isoforms: characterization of their distribution in rat brain and their agmatinase activity , 2016, Histochemistry and Cell Biology.

[3]  Giovanni Coppola,et al.  Integrated genomics and proteomics to define huntingtin CAG length-dependent networks in HD Mice , 2016, Nature Neuroscience.

[4]  R. Snell,et al.  Identification of elevated urea as a severe, ubiquitous metabolic defect in the brain of patients with Huntington's disease. , 2015, Biochemical and biophysical research communications.

[5]  M. Aschner,et al.  Manganese Is Essential for Neuronal Health. , 2015, Annual review of nutrition.

[6]  M. Aschner,et al.  A novel manganese-dependent ATM-p53 signaling pathway is selectively impaired in patient-based neuroprogenitor and murine striatal models of Huntington's disease. , 2015, Human molecular genetics.

[7]  G. Schenk,et al.  Insight on the interaction of an agmatinase-like protein with Mn(2+) activator ions. , 2015, Journal of inorganic biochemistry.

[8]  R. Caldwell,et al.  Arginase 2 Deficiency Prevents Oxidative Stress and Limits Hyperoxia-Induced Retinal Vascular Degeneration , 2014, PloS one.

[9]  T. Magalhães,et al.  Anatomical Region Differences and Age-Related Changes in Copper, Zinc, and Manganese Levels in the Human Brain , 2014, Biological Trace Element Research.

[10]  Y. Bergman,et al.  Transcriptional Regulation of Endothelial Arginase 2 by Histone Deacetylase 2 , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[11]  M. Aschner,et al.  Considerations on manganese (Mn) treatments for in vitro studies. , 2014, Neurotoxicology.

[12]  M. Jaworska,et al.  Huntington' disease--imbalance of amino acid levels in plasma of patients and mutation carriers. , 2013, Annals of agricultural and environmental medicine : AAEM.

[13]  D. Fulton,et al.  The Subcellular Compartmentalization of Arginine Metabolizing Enzymes and Their Role in Endothelial Dysfunction , 2013, Front. Immunol..

[14]  David H Salat,et al.  Alterations in brain transition metals in Huntington disease: an evolving and intricate story. , 2012, Archives of neurology.

[15]  Frances H Arnold,et al.  SCHEMA-designed variants of human Arginase I and II reveal sequence elements important to stability and catalysis. , 2012, ACS synthetic biology.

[16]  W. Hanneman,et al.  Gene deletion of nos2 protects against manganese-induced neurological dysfunction in juvenile mice. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[17]  M. Aschner,et al.  Disease-Toxicant Interactions in Manganese Exposed Huntington Disease Mice: Early Changes in Striatal Neuron Morphology and Dopamine Metabolism , 2012, PloS one.

[18]  D. Friedman,et al.  Changes in the striatal proteome of YAC128Q mice exhibit gene-environment interactions between mutant huntingtin and manganese. , 2012, Journal of proteome research.

[19]  Blair R. Leavitt,et al.  Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease , 2012, Neurobiology of Disease.

[20]  M. Aschner,et al.  Gender and manganese exposure interactions on mouse striatal neuron morphology. , 2011, Neurotoxicology.

[21]  R. Caldwell,et al.  Arginase 2 Deletion Reduces Neuro-Glial Injury and Improves Retinal Function in a Model of Retinopathy of Prematurity , 2011, PloS one.

[22]  T. Wynn,et al.  Quantitative assessment of macrophage functions in repair and fibrosis. , 2011, Current protocols in immunology.

[23]  M. Calcutt,et al.  Discovery of an operon that participates in agmatine metabolism and regulates biofilm formation in Pseudomonas aeruginosa , 2010, Molecular microbiology.

[24]  M. Aschner,et al.  Disease‐toxicant screen reveals a neuroprotective interaction between Huntington’s disease and manganese exposure , 2010, Journal of neurochemistry.

[25]  Hsiao-Wen Chen,et al.  The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system. , 2009, Human molecular genetics.

[26]  P. Greengard,et al.  Resource Application of a Translational Profiling Approach for the Comparative Analysis of CNS Cell Types , 2009 .

[27]  Y. Xing,et al.  A Transcriptome Database for Astrocytes, Neurons, and Oligodendrocytes: A New Resource for Understanding Brain Development and Function , 2008, The Journal of Neuroscience.

[28]  D. Perl,et al.  The Neuropathology of Manganese-Induced Parkinsonism , 2007, Journal of neuropathology and experimental neurology.

[29]  Michael Aschner,et al.  Speciation of manganese in cells and mitochondria: a search for the proximal cause of manganese neurotoxicity. , 2006, Neurotoxicology.

[30]  Daniel L Ward,et al.  Basal Ganglia Accumulation and Motor Assessment Following Manganese Chloride Exposure in the C57BL/6 Mouse , 2005, International journal of toxicology.

[31]  Patrik Brundin,et al.  The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies , 2005, NeuroRX.

[32]  L. Nelin,et al.  Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[33]  B. Escalante,et al.  Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington’s disease mutation , 2002, Brain Research.

[34]  W. Grody,et al.  Mouse Model for Human Arginase Deficiency , 2002, Molecular and Cellular Biology.

[35]  H. Wiesinger.  Arginine metabolism and the synthesis of nitric oxide in the nervous system , 2001, Progress in Neurobiology.

[36]  H. Zoghbi,et al.  Generation of a Mouse Model for Arginase II Deficiency by Targeted Disruption of the Arginase II Gene , 2001, Molecular and Cellular Biology.

[37]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[38]  N. Kuhn,et al.  pH-sensitive control of arginase by Mn(II) ions at submicromolar concentrations. , 1991, Archives of biochemistry and biophysics.

[39]  S. Doré,et al.  Protective Role of Arginase II in Cerebral Ischemia and Excitotoxicity. , 2016, Journal of neurology and neuroscience.